For institutional investors in the UK

Global Perspectives

Global Dividend Index

The first of its kind, quarterly, long-term study into global dividend trends.

Equity Perspectives

Quarterly insight from our equity teams to help clients navigate the markets and opportunities ahead.

Fixed Income Perspectives

Quarterly insight from our fixed income teams to help clients navigate the markets and opportunities ahead.

Decarbonisation in EM Index

Perspectives and insights on Mexico, Central America and the Caribbean, and South America.

Alternative Perspectives

Insight from our alternatives team to help clients navigate the markets and opportunities ahead.

Sovereign Debt Index

A long-term study into trends in government indebtedness, with the investment opportunities and risks it presents.

Latest Insights

Subscribe for relevant insights delivered straight to your inbox

The growing importance of alternatives in an inflationary environment

The growing importance of alternatives in an inflationary environment

Portfolio manager James de Bunsen considers if alternative assets can help multi-asset investors to navigate this current point in the economic cycle.

One Down, Three to Go

One Down, Three to Go

Updated strategist predictions for 2022 and a look at the relationship between first quarter and rest of year returns.

2022 – optimal conditions for a liquid alternative toolset?

2022 – optimal conditions for a liquid alternative toolset?

How can a multi-strategy approach to using liquid alternatives help to improve diversification and complement traditional asset class allocations?

Keep calm and (commodity) carry on

Keep calm and (commodity) carry on

Volatility and noise in financial markets increased markedly in the first quarter of 2022. Can investors find a useful signal in commodity markets that can shed some light in a somewhat uncertain world?

Beating the biotech blues

Beating the biotech blues

The biotech sector is experiencing its worst period of relative underperformance on record. But some of history’s biggest biotech pains have been followed by memorable gains.